Elevated Aβ42 in aged, non-demented individuals with cerebral atherosclerosis

Current Alzheimer Research

Volumn 10, Issue 8, 2013, Pages 785-789

  Sadleir, Katherine R ^a   Bennett, David A ^b   Schneider, Julie A ^b   Vassar, Robert ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

A ; Alzheimer's disease; Amyloid; Atherosclerosis; BACE1; eIF2

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BETA SECRETASE 1; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; OXYGEN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN CIRCULATION; BRAIN CIRCULUS ARTERIOSUS; BRAIN HOMOGENATE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENERGY; FEMALE; FRONTAL CORTEX; HEART INFARCTION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PROTEIN CONTENT;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; CIRCLE OF WILLIS; FEMALE; FRONTAL LOBE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; PEPTIDE FRAGMENTS;

EID: 84888047146     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990152     Document Type: Article

References (28)

1. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 6(1): 27 (2011).
2. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735-41 (1999).
3. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, et al. Betasite amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 27(14): 3639-49 (2007).
4. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60(6): 988-1009 (2008).
5. Chami L, Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Mol Neurodegener 7: 52 (2012).
6. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25(47): 10874-83 (2005).
7. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103(49): 18727-32 (2006).
8. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 1009(1-2): 1-8 (2004).
9. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, et al. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 112(3): 455-69 (2005).
10. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101(1): 284-9 (2004).
11. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res 25(6): 605-10 (2003).
12. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke; a journal of cerebral circulation 33(8): 1986-92 (2002).
13. Roher AE, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, Emmerling MR, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimer's & dementia: the journal of the Alzheimer's Association 7(4): 436-44 (2011).
14. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta neuropathologica 113(1): 13-21 (2007).
15. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, et al. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 23(11): 2055-62 (2003).
16. Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain: a journal of neurology. 2012 Dec; 135(Pt 12): 3749-56.
17. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18(2): 240-52 (2008).
18. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 9(6): 646-63 (2012).
19. Zetterberg H, Mortberg E, Song L, Chang L, Provuncher GK, Patel PP, et al. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PLoS One 6(12): e28263 (2011).
20. Soneira CF, Scott TM. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin Anat 9(2): 118-27 (1996).
21. Walsh DM, Selkoe DJ. A beta oligomers-a decade of discovery. J Neurochem 101(5): 1172-84 (2007).
22. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120(4): 545-55 (2005).
23. Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer's disease: synapses gone cold. Mol Neurodegener 6(1): 63 (2011).
24. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461(7266): 916-22 (2009).
25. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38(11): 1682-7 (1988).
26. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 72(4): 599-609 (2012).
27. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain barrier disorder in Alzheimer's disease. Acta Neuro pathologica 118(1): 103-13 (2009).
28. Sadleir KR, Vassar R. Cdk5 protein inhibition and Abeta42 increase BACE1 protein level in primary neurons by a posttranscriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. J Biol Chem 287(10): 7224-35 (2012).